<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03466671</url>
  </required_header>
  <id_info>
    <org_study_id>UMIN000031412</org_study_id>
    <nct_id>NCT03466671</nct_id>
  </id_info>
  <brief_title>A Trial of TTA-121 on Autism Spectrum Disorder</brief_title>
  <official_title>An Early Phase II Trial for Efficacy and Safety of TTA-121 on Autism Spectrum Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamamatsu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Japan Agency for Medical Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hamamatsu University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test efficacy and safety of a novel nasal spray of oxytocin on social deifies in autism&#xD;
      spectrum disorder, and To compare effect sizes of different doses&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 27, 2018</start_date>
  <completion_date type="Anticipated">March 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 16, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy on autism spectrum social core symptom assessed by social reciprocity score on the Autism Diagnostic Observation Schedule module 4</measure>
    <time_frame>At baseline, which was before and on the same day as the first administration, and at endpoint, which was started approximately 15 min after the last drug administration</time_frame>
    <description>Changes in social reciprocity score (range: 0-14, Higher value represent a worth outcome) on Autism Diagnostic Observation Schedule module 4 between baseline and endpoint of each administration period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy on autism spectrum core symptom assessed by communication score on the Autism Diagnostic Observation Schedule module 4</measure>
    <time_frame>At baseline, which was before and on the same day as the first administration, and at endpoint, which was started approximately 15 min after the last drug administration</time_frame>
    <description>Changes in communication score (range: 0-8, Higher value represent a worth outcome) on Autism Diagnostic Observation Schedule module 4 between baseline and endpoint of each administration period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy on autism spectrum core symptom assessed by repetitive and restricted behavior score on the Autism Diagnostic Observation Schedule module 4</measure>
    <time_frame>At baseline, which was before and on the same day as the first administration, and at endpoint, which was started approximately 15 min after the last drug administration</time_frame>
    <description>Changes in repetitive and restricted behavior score (range: 0-10, Higher value represent a worth outcome) on Autism Diagnostic Observation Schedule module 4 between baseline and endpoint of each administration period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy on autism spectrum core symptom assessed by revised algorithm score of social affect on the Autism Diagnostic Observation Schedule module 4</measure>
    <time_frame>At baseline, which was before and on the same day as the first administration, and at endpoint, which was started approximately 15 min after the last drug administration</time_frame>
    <description>Changes in revised algorithm score of social affect (range: 0-20, Higher value represent a worth outcome) on Autism Diagnostic Observation Schedule module 4 between baseline and endpoint of each administration period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy on autism spectrum core symptom assessed by revised algorithm of repetitive and restricted behavior score on the Autism Diagnostic Observation Schedule module 4</measure>
    <time_frame>At baseline, which was before and on the same day as the first administration, and at endpoint, which was started approximately 15 min after the last drug administration</time_frame>
    <description>Changes in revised algorithm of repetitive and restricted behavior score (range: 0-10, Higher value represent a worth outcome) on Autism Diagnostic Observation Schedule module 4 between baseline and endpoint of each administration period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by Clinical Global Impression-Improvement</measure>
    <time_frame>At baseline, which was before and on the same day as the first administration, and at endpoint, which was assessed within 100 min after the last drug administration</time_frame>
    <description>Changes in Clinical Global Impression-Improvement (range: 1-7, Higher value represent a worse outcome) between baseline and endpoint of each administration period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by Clinical Global Impression-Severity</measure>
    <time_frame>At baseline, which was before and on the same day as the first administration, and at endpoint, which was assessed within 100 min after the last drug administration</time_frame>
    <description>Changes in Clinical Global Impression-Severity (range: 1-7, Higher value represent a worse outcome) between baseline and endpoint of each administration period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by Global Assessment of Functioning</measure>
    <time_frame>At baseline, which was before and on the same day as the first administration, and at endpoint, which was assessed within 100 min after the last drug administration</time_frame>
    <description>Changes in Global Assessment of Functioning (range: 1-100, Higher value represent a better outcome) between baseline and endpoint of each administration period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by gaze fixation time on social region</measure>
    <time_frame>At baseline, which was before and on the same day as the first administration, and at endpoint, which was started approximately 60 min after the last drug administration</time_frame>
    <description>Changes in gaze fixation time on social region during being talked between baseline and endpoint of each administration period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by quantitative analysis of facial expression</measure>
    <time_frame>At baseline, which was before and on the same day as the first administration, and at endpoint, which was started approximately 15 min after the last drug administration</time_frame>
    <description>Changes in quantitative measure of facial expression on videos recorded during ADOS administration between baseline and endpoint of each administration period</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Low dose once per day and placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Four weeks administrations of TTA-121 3U once per day in morning and placebo once per day in evening.&#xD;
After four weeks washout, four weeks administrations of placebo twice per day in morning and evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose twice per day and placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Four weeks administrations of TTA-121 3U twice per day in morning and evening. After four weeks washout, four weeks administrations of placebo twice per day in morning and evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose once per day and placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Four weeks administrations of TTA-121 10U once per day in morning and placebo once per day in evening.&#xD;
After four weeks washout, four weeks administrations of placebo twice per day in morning and evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose twice per day and placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Four weeks administrations of TTA-121 10U twice per day in morning and evening. After four weeks washout, four weeks administrations of placebo twice per day in morning and evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and low dose once per day</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 3U once per day in morning and placebo once per day in evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and low dose twice per day</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 3U twice per day in morning and evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and high dose once per day</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 10U once per day in morning and placebo once per day in evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and high dose twice per day</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 10U twice per day in morning and evening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTA-121</intervention_name>
    <description>A nove intranasal spray of oxytocin and placebo</description>
    <arm_group_label>High dose once per day and placebo</arm_group_label>
    <arm_group_label>High dose twice per day and placebo</arm_group_label>
    <arm_group_label>Low dose once per day and placebo</arm_group_label>
    <arm_group_label>Low dose twice per day and placebo</arm_group_label>
    <arm_group_label>Placebo and high dose once per day</arm_group_label>
    <arm_group_label>Placebo and high dose twice per day</arm_group_label>
    <arm_group_label>Placebo and low dose once per day</arm_group_label>
    <arm_group_label>Placebo and low dose twice per day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of autism spectrum disorder based on Diagnostic and Statistical Manual of&#xD;
             Mental Disorders-V with score exceeding the cut-off value of 10 for qualitative&#xD;
             abnormalities in social reciprocity on Autism Diagnostic Interview Revised (ADIR)&#xD;
&#xD;
          2. Full scale Intelligent quotient above 80 as measured using the Wechsler Adult&#xD;
             Intelligent Scale-III&#xD;
&#xD;
          3. Written informed consent for participating the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of bipolar disorder or schizophrenia spectrum disorder&#xD;
&#xD;
          2. Primary diagnosis of depressive disorders, obsessive-compulsive and related disorders,&#xD;
             anxiety disorders, trauma- and stressor-related disorders, dissociative disorders,&#xD;
             somatic symptom and related disorders, or neurodevelopmental disorders other than&#xD;
             autism spectr um disorder&#xD;
&#xD;
          3. Instability in symptoms of comorbid mental disorders such as depressive disorders or&#xD;
             anxiety disorders&#xD;
&#xD;
          4. History of changes in medication or doses of psychotropics within one month before&#xD;
             registration&#xD;
&#xD;
          5. Current treatment with more than one psychotropics&#xD;
&#xD;
          6. History of hyper-sensitivity to oxytocin&#xD;
&#xD;
          7. History of seizures or traumatic brain injury with loss of consciousness for longer&#xD;
             than 5 minutes&#xD;
&#xD;
          8. History of alcohol-related disorders, substance abuse, or addiction&#xD;
&#xD;
          9. Family history of male breast cancer&#xD;
&#xD;
         10. Subject who has severe complications&#xD;
&#xD;
         11. Known hypersensitivity to some drugs and foods&#xD;
&#xD;
         12. Subject who is not able to consent contraception during study period&#xD;
&#xD;
         13. Participation in another registration clinical trial and administration of&#xD;
             investigational drug during 120 days before informed consent&#xD;
&#xD;
         14. Other Subjects whom a lead investigator or the patient's primary physician deems are&#xD;
             not appropriate for this study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hidenori Yamasue, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Psychiatry, Hamamatsu University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hamamatsu University School of Medicine</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <zip>431-3192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>February 28, 2018</study_first_submitted>
  <study_first_submitted_qc>March 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2018</study_first_posted>
  <last_update_submitted>December 18, 2019</last_update_submitted>
  <last_update_submitted_qc>December 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hamamatsu University</investigator_affiliation>
    <investigator_full_name>Hidenori Yamasue, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

